|
Elranatamab (Elra) Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 1: 1
Top Sponsors
- University of Illinois Chicago1
Indications
- Consolidation1
- HIV1
- Plasmablastic Lymphoma1
- Cancer1
Chicago, Illinois1 trial
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
University of Illinois at Chicago
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.